LITFULO ritlecitinib

Drug Class

JAK3/TEC family kinase inhibitor

Mechanism

Ritlecitinib irreversibly inhibits Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinases, blocking common gamma-chain cytokine signaling.

Approved Indication

Treatment of severe alopecia areata in adults and adolescents 12 years of age and older.

What This Means For Patients

LITFULO is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2023) — Sources
• EMA — Approved (2023) — Sources
• NMPA — Approved (2023) — Sources

Pivotal Clinical Evidence

• ALLEGRO — King et al., Lancet 2023 (NCT03732807) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215830s000lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/litfulo
• https://doi.org/10.1016/S0140-6736(23)00222-2